
Infinity Pharmaceutical Inc (NASDAQ:INFI)’s IPI-145 has the potential to become the best in class PI3K inhibitor
Boston, MA 07/23/2013 (wallstreetpr) – More recently, Infinity Pharmaceutical Inc (NASDAQ:INFI) has reported the results from an ongoing phase 1 study of the drug IPI-145. Per













